Cargando…
A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection
FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Present guidelines endorse complete removal of cardiovascular-implantable electronic devices (pacemakers/defibrillators), including extraction of intracardiac electrodes, not only for systemic infections but also for localized &quo...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206707/ http://dx.doi.org/10.1093/europace/euad122.502 |
_version_ | 1785046288306274304 |
---|---|
author | Chorin, E Topaz, M Schwartz, A L Hochstadt, A Shotan, A Ashkenazi, I Kazatsker, M Nof, E Beinart, R Glikson, M Mazo, A Milman, A Banai, S Rosso, R Viskin, S |
author_facet | Chorin, E Topaz, M Schwartz, A L Hochstadt, A Shotan, A Ashkenazi, I Kazatsker, M Nof, E Beinart, R Glikson, M Mazo, A Milman, A Banai, S Rosso, R Viskin, S |
author_sort | Chorin, E |
collection | PubMed |
description | FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Present guidelines endorse complete removal of cardiovascular-implantable electronic devices (pacemakers/defibrillators), including extraction of intracardiac electrodes, not only for systemic infections but also for localized "pocket infections." OBJECTIVES: We evaluated the efficacy of delivering "Continuous, In-situ-Targeted, ultra-high concentration of Antibiotics" (CITA) into the infected subcutaneous the device-pocket, obviating the need for device/lead-extraction. METHODS: The CITA-Group consisted of 80 patients with pocket infection who were treated with CITA during 2007-2021. Of them, nine patients declined lead-extraction because of prohibitive operative risk, and six patients had questionable indications for extraction. The remaining 65 patients with pocket infection, who were eligible for extraction but opted for CITA treatment, were compared to 81 patients with pocket infection and similar characteristics who underwent device/lead-extraction as primary therapy. RESULTS: Eighty patients with pocket infection were treated with CITA during 2007-2021. CITA was curative in 85% (68/80) patients, who remained free of infection (median follow-up: 3 years, interquartile range 1 – 6.8 years). In the case-control study of CITA vs. device/lead extraction, cure rates were higher after device/lead-extraction than after CITA [96.2%; (78/81) vs. 84.6%; (55/65), p=0.027]. However, rates of serious complications were also higher after extraction [12 (14.8%) vs. 1 (1.5%), p=0.005]. All-cause 1-month and 1-year mortality were similar for CITA and device/lead-extraction (0% vs. 3·7%, p=0·25 and 12·3% vs. 13·6%, p=1·00, respectively). Extraction was avoided in 90·8% (59/65) extraction-eligible patients treated with CITA. CONCLUSIONS: CITA is a safe and effective alternative for patients with pocket infection who are unsuitable or unwilling to undergo extraction. [Figure: see text] |
format | Online Article Text |
id | pubmed-10206707 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102067072023-05-25 A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection Chorin, E Topaz, M Schwartz, A L Hochstadt, A Shotan, A Ashkenazi, I Kazatsker, M Nof, E Beinart, R Glikson, M Mazo, A Milman, A Banai, S Rosso, R Viskin, S Europace 14.5 - Device Complications and Lead Extraction FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Present guidelines endorse complete removal of cardiovascular-implantable electronic devices (pacemakers/defibrillators), including extraction of intracardiac electrodes, not only for systemic infections but also for localized "pocket infections." OBJECTIVES: We evaluated the efficacy of delivering "Continuous, In-situ-Targeted, ultra-high concentration of Antibiotics" (CITA) into the infected subcutaneous the device-pocket, obviating the need for device/lead-extraction. METHODS: The CITA-Group consisted of 80 patients with pocket infection who were treated with CITA during 2007-2021. Of them, nine patients declined lead-extraction because of prohibitive operative risk, and six patients had questionable indications for extraction. The remaining 65 patients with pocket infection, who were eligible for extraction but opted for CITA treatment, were compared to 81 patients with pocket infection and similar characteristics who underwent device/lead-extraction as primary therapy. RESULTS: Eighty patients with pocket infection were treated with CITA during 2007-2021. CITA was curative in 85% (68/80) patients, who remained free of infection (median follow-up: 3 years, interquartile range 1 – 6.8 years). In the case-control study of CITA vs. device/lead extraction, cure rates were higher after device/lead-extraction than after CITA [96.2%; (78/81) vs. 84.6%; (55/65), p=0.027]. However, rates of serious complications were also higher after extraction [12 (14.8%) vs. 1 (1.5%), p=0.005]. All-cause 1-month and 1-year mortality were similar for CITA and device/lead-extraction (0% vs. 3·7%, p=0·25 and 12·3% vs. 13·6%, p=1·00, respectively). Extraction was avoided in 90·8% (59/65) extraction-eligible patients treated with CITA. CONCLUSIONS: CITA is a safe and effective alternative for patients with pocket infection who are unsuitable or unwilling to undergo extraction. [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10206707/ http://dx.doi.org/10.1093/europace/euad122.502 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | 14.5 - Device Complications and Lead Extraction Chorin, E Topaz, M Schwartz, A L Hochstadt, A Shotan, A Ashkenazi, I Kazatsker, M Nof, E Beinart, R Glikson, M Mazo, A Milman, A Banai, S Rosso, R Viskin, S A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection |
title | A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection |
title_full | A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection |
title_fullStr | A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection |
title_full_unstemmed | A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection |
title_short | A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection |
title_sort | novel antibiotic delivery approach for salvage of cardiovascular-implantable electronic devices with localized infection |
topic | 14.5 - Device Complications and Lead Extraction |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206707/ http://dx.doi.org/10.1093/europace/euad122.502 |
work_keys_str_mv | AT chorine anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT topazm anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT schwartzal anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT hochstadta anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT shotana anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT ashkenazii anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT kazatskerm anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT nofe anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT beinartr anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT gliksonm anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT mazoa anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT milmana anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT banais anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT rossor anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT viskins anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT chorine novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT topazm novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT schwartzal novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT hochstadta novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT shotana novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT ashkenazii novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT kazatskerm novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT nofe novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT beinartr novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT gliksonm novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT mazoa novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT milmana novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT banais novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT rossor novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection AT viskins novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection |